Medical Insights with Dr. Thomas Blom
In this episode of Medical Insights, Dr. Thomas Blom sits down with Dr. Sheetal Shrimanker, a hematologist-oncologist at Penn Medicine, to demystify the complex world of plasma cell disorders. Receiving a lab result showing an "abnormal protein" can be a frightening experience. Dr. Shrimanker explains exactly what a monoclonal protein is, how physicians risk-stratify patients, and the crucial differences between a benign condition like MGUS and active Multiple Myeloma. In This Episode: * The First Red Flag: What is a monoclonal protein and why is it often found by accident? * MGUS vs. Smoldering Myeloma: Understanding the 1% annual risk of progression and when a bone marrow biopsy is necessary. * The CRAB Criteria: How specialists look for end-organ damage (Calcium, Renal, Anemia, Bone). * Modern Staging: Why traditional cancer stages don't apply to blood cancers and how cytogenetics (DNA testing) dictates the plan. * Treatment Pathways: A look at induction therapy, stem cell transplants, and the role of medications like Daratumumab. * The Future of Care: An introduction to Bi-specific Antibodies and CAR T-cell therapy. About Our Guest: Dr. Sheetal Shrimanker is a board-certified hematologist-oncologist practicing with Penn Medicine in Princeton, New Jersey. She specializes in treating blood-based malignancies and guiding patients through complex immunotherapy and transplant journeys. 0:00 Introduction to Monoclonal Proteins 2:24 Workup for Monoclonal Proteins (MGUS) 4:43 Criteria for Bone Marrow Biopsy & Imaging 6:23 Causes of MGUS (Viruses & Autoimmune) 7:42 Prognosis and Risk Counseling 9:39 Distinguishing MGUS, Smoldering Myeloma, and Multiple Myeloma 11:42 Staging and Cytogenetics 14:48 Treatment Pathways & Induction Therapy 18:34 Stem Cell Transplants 19:56 Managing Risks (Infection, Blood Clots) 22:36 Future Care: CAR T-Cell Therapy 24:28 Bi-specific Antibodies 26:53 Treating Smoldering Myeloma 28:34 Genetic Predisposition 29:52 Monoclonal Gammopathy of Renal/Neurological Significance 31:52 Related Disorders (Waldenström’s & Amyloidosis) 34:19 Long-term Management, Maintenance, and IVIG #cancerresearch
8 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Medical Insights with Dr. Thomas Blom!